Authors:
Davis, JC
Totoritis, MC
Rosenberg, J
Sklenar, TA
Wofsy, D
Citation: Jc. Davis et al., Phase I clinical trial of a monoclonal antibody against CD40-Ligand (IDEC-131) in patients with systemic lupus erythematosus, J RHEUMATOL, 28(1), 2001, pp. 95-101
Authors:
Wada, T
Schwarting, A
Chesnutt, MS
Wofsy, D
Kelley, VR
Citation: T. Wada et al., Nephritogenic cytokines and disease in MRL-Fas(lpr) kidneys are dependent on multiple T-cell subsets, KIDNEY INT, 59(2), 2001, pp. 565-578
Citation: Di. Daikh et D. Wofsy, Cutting edge: Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide, J IMMUNOL, 166(5), 2001, pp. 2913-2916
Citation: B. Diamond et al., The immune tolerance network and rheumatic disease - Immune tolerance comes to the clinic, ARTH RHEUM, 44(8), 2001, pp. 1730-1735
Authors:
Jeddi, P
Keusch, J
Lydyard, PM
Bodman-Smith, KB
Chesnutt, MS
Wofsy, D
Hirota, H
Taga, T
Delves, PJ
Citation: P. Jeddi et al., The effect on immunoglobulin glycosylation of altering in vivo production of immunoglobulin G, IMMUNOLOGY, 98(3), 1999, pp. 475-480
Citation: Di. Daikh et D. Wofsy, Treatment of systemic lupus erythematosus by selective inhibition of T-cell function, CONT IMMUN, 7, 1999, pp. 642-655
Citation: Di. Daikh et D. Wofsy, On the horizon: Clinical trials of new immunosuppressive strategies for autoimmune diseases, TRANSPLAN P, 30(8), 1998, pp. 4027-4028